awmsg logo



ranibizumab (Lucentis®)


Reference No. 3233

Publication date:
12/06/2018


Appraisal information

ranibizumab (Lucentis®) 10 mg/ml solution for injection


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Eye
NMG meeting date: 11/04/2018
AWMSG meeting date: 23/05/2018
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0718
Ratification by Welsh Government: 11/06/2018

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Ranibizumab (Lucentis®) is recommended as an option for use within NHS Wales for the treatment of visual impairment in adults due to choroidal neovascularisation not due to pathological myopia or wet age-related macular degeneration. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Final Appraisal Recommendation (FAR)
Download